Good morning, ladies and gentlemen, and welcome to Henry Schein’s Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this call is being recorded. I would now like to introduce your host for today’s call, Graham Stanley, Henry Schein, Vice President of Investor Relations and Strategic Financial Project Officer. Thank you, sir. Please go ahead, Graham.

Thank you, operator, and my thanks to each of you for joining us to discuss Henry Schein’s Financial Results for the third quarter of 2022. With me on the call today are Stanley Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein; and Ron South, Senior Vice President and Chief Financial Officer. Before we begin, I’d like to state that certain comments made during this call will include information that’s forward-looking. As you know, risks and uncertainties involved in the company’s business may affect the matters referred to in forward-looking statements. As a result, the company’s performance may materially differ from those expressed in or indicated by such statements. These forward-looking statements are qualified in their entirety by the cautionary statements contained in Henry Schein’s filings with the Securities and Exchange Commission and included in the Risk Factors section of those filings. In addition, all comments about the markets we serve, including end market growth rates and market share, are based upon the company’s internal analysis and estimates. Our conference call remarks will include both GAAP and non-GAAP financial results. We believe the non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented certainly for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures. Reconciliations between GAAP and non-GAAP measures can be found in the Supplemental Information section of our Investor Relations website and in Exhibit B of today’s press release, which is also available in the Investor Relations section of our website. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 1, 2022. Henry Schein undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Finally, we have also prepared a presentation summarizing our third quarter financial results. This can also be found in the Investor Relations section of our website. During today’s Q&A session, please limit yourself to a single question and a follow-up. And with that, I’d like to turn the call over to Stanley Bergman.

Thank you, Graham. Good morning, everyone, and thank you everyone for joining us on this call today. Our financial results for the third quarter of 2022 reflect solid underlying growth across our business and actually most geographies. We grew our non-GAAP diluted EPS compared with third quarter 2021 and this is despite the significant currency headwinds and lower sales of PPE and COVID test kits. Today, we are narrowing our 2022 non-GAAP diluted EPS guidance range, which reflects our confidence in the underlying strength and the stability of our business. Overall, we feel very good about the outlook for the company and remain highly focused on delivering on our both plus one strategy, which we’re happy to go into details during the Q&A period and as we continue to increase the sustainable profitability of the business. Importantly, current market demands in both our dental and medical businesses are generally stable and actually have been this way for a while. We continue to receive price increases from various suppliers, with additional price changes towards the end of the second quarter. The depth and breadth of the Henry Schein portfolio allows us to satisfy customer needs, and to offer alternative national brand and corporate brand products to price-sensitive customers, thus positioning us to also protect our gross profit. This is reflective of a deep and lasting relationship we have with our customers and our suppliers. As we commented in the previous quarters, market prices for gloves continue to decrease. However, we believe at a reduced pace, while our unit volume for gloves is relatively stable, and this is driving lower sales and profits in the PPE category. Remember, the PPE category is largely gloves. Similarly, sales and profit for COVID test kits have declined compared to the prior year. But pricing and volume for these products is also stabilizing. So generally, the PPE market on gloves has deflated. Volumes are definitely stable. And COVID-19 tests are relatively stable from a pricing point of view and the volume point of view compared to the previous year. So we’ll of course provide further information on the whole PPE and COVID test category. Having said that, our business excluding PPE and COVID tests did perform quite well as we will discuss in detail during this call. So let me start by reviewing performance highlights for each of our business units starting with the dental distribution business. Internal growth in local currency of global dental sales, excluding PPE was good. Consumable merchandise growth, excluding PPE was solid and we were especially pleased with the excellent growth of our North American equipment business and continued strength in our global equipment order book. We have a strong growth in sales of traditional equipment during the third quarter. We are also experiencing continuing good demand for high-tech equipment, an area where Henry Schein is a global leader and this is because dental practices look to secure and maintain a competitive advantage and the product offering available in the space has expanded and there is practically something for every dental practice. So this growth was largely driven by volume. As we’re seeing new innovation in digital dental equipment come to markets at somewhat lower average selling prices. But the market is significant. Big opportunity, lots of units, and we have a very good offering. We believe that consumable merchandise sales growth in Europe was impacted this year because of the summer holiday season, as dental practitioners and patients took more vacation days than the previous year. But we also believe that our consumable merchandise growth in Europe will remain stable, leaning slightly positively. On the other side of the coin, other parts of the world in international growth could benefit from ongoing strengths in Australia, New Zealand, and Brazil, which was partially offset by continuing lockdowns in China; having said that, our China business is relatively small compared to our total business. The North American equipment order book remains robust and continues to grow from last quarter and this is partly a result of quite a successful DS from our point of view. This event was held late in the third quarter compared to the previous year when it was earlier and we saw continuing demand for intraoral imaging, chair-side mills, 2D, 3D digital, extraoral imaging devices, and 3D printing with a number of other manufacturers too and of course, all the CAD CAM lines work that well also from an audit taking point of view leading to probably a stronger than believed fourth quarter in a market that we’re doing quite well in generally. Lead times for additional equipment are reducing slightly. For the installations are still being affected by delays within office construction. So we expect our demand and our sales in the equipment area to continue to be strong. Our international equipment order book is also solid. So dental growth during the third quarter was aided by, as investors know, Midway dental acquisition, which strengthened our long-standing presence in the Midwest of the United States, providing dental customers of Midway with access to an expanded portfolio of solutions. And of course, a highly competitive pricing. Midway builds an excellent reputation within the industry over the past 35 years and the vision of senior executives at Midway strongly aligns with the Henry Schein commitment to helping dentists operate a more efficient practice while allowing a focus by the dentist on delivering high-quality patient care. We have successfully completed the integration of the Midway dental business distribution business and the Condor dental that we recently acquired in Switzerland, that is on the distribution side is also largely completed from an integration point of view. So we continue to invest in our dental specialty portfolio and add new customers. Sales to DSO customers in the United States once again were good in the specialty areas and demonstrate success of our shine strategic initiative. We are seeing some signs of economic caution in several specialty markets regarding high-end oral surgery procedures. I would not say this is the case as relates to endodontics. Oral Surgery is some caution on the high-end side of implants. And our orthodontic business is relatively small in a minute. But importantly, we believe that Henry Schein is well positioned to capitalize on these shifts, specifically in the oral surgery market as we offer a full range of dental implant options at various price points. So we think on the unit side, we will continue to do well and also on the profit side. So we had strong growth in our clear aligner business. Of course, let me remind those participating in today’s calls our aligner business is relatively small, but it is growing nicely and specifically with some DSOs. And again, as I mentioned, we are seeing solid demand for our endodontic specialty products, which is driven by sales of new products, particularly Triton irrigation solution and our EdgePRO laser system. Both of these have done well. But I would also say units of endo have done relatively well. And so we believe that our dental specialty business is doing quite well from a foundation point of view and we always need to look at comparable quarters in previous years, trends etc. and I think the business is in pretty good shape. Let’s move on to the technology and value-added services. Our technology and value-added services businesses had good underlying sales growth in the third quarter. Sales growth was impacted by the expiration of the modestly profitable but significant large government contracts. The largest business in the segment is Henry Schein owned software business, which once again posted solid sales growth domestically and internationally, driven by our Dentrix practice management software it and Dentrix Ascend and entirely cloud-based solutions. During the quarter, we surpassed 5,000 cloud-based customers, and in more than 1,000 new customers year-to-date, and currently exceeding 100 new installations per month. We have launched entirely across the United Kingdom and in Australia, New Zealand as well over the past six months and remain on track to further geographic expansion in 2023. Ascend has been growing its customer base by double-digit percentages, quarter-to-quarter. Notably, these cloud-based practice management systems also drive traction for other Henry Schein owned solutions and for effect stickiness to the entire Henry Schein portfolio. We recently announced that Dentrix Ascend was selected as the exclusive cloud-based practice management system of small brands, a dental service organization a DSO organization, with more than 700 locations, reflecting the competitive advantage of this product offering. So an important part of the BOLD one strategic plan is to place greater emphasis on these high growth, high margin products and services. Of course, no guarantees. But this is an area of focus for inorganic growth. And we feel that we’re on track to deliver on our expectations in that area with inorganic growth, although we will announce any opportunities in that area or any deals in that area once those deals are closed, and there’s no certainty as to when that may be. So another bright spot in the organization in our performance, the sales growth in local currencies and our medical business continued, which continued to be excellent during the third quarter when excluding PPE and COVID tests kits largely pricing issues, PPE related to gloves, and tests kits just relating to demand for the test kits which we’ve discussed on several calls in the past, our expectations were relatively in line on the test kits, specifically. So we are continuing to deepen our relationships with existing large IDM customers while nicely growing our other medical businesses. We are especially pleased with strong growth in our government sector of school accounts and we continue to make solid progress in gaining business from independent physicians although several years ago this group reduced, there is still at the reduced the number of independent physicians, it is relatively stable group today. And we continue to gain market share within that group. And post admitting the smaller medical groups are also areas where we’re adding customers and market share we believe. Our focus on equipment, pharmaceutical products, and point of care diagnostics remain bright spots in this business, although I must say the whole of the medical business was doing well. Of course, the volatility of sales in COVID-19 test kits which went down dramatically in earlier quarters has moderated but the post at a lower level of sales and on the PPE glove side the volume is stable, but the pricing is still somewhat unstable but less volatile than we saw in earlier quarters. Third quarter sales growth had a challenging prior year comparison, when patient traffic to physician office says was bolstered by a surge in Delta variants, and that tough comparisons will continue in the fourth quarter. Yet we expect medical sales growth excluding PPE and tests to continue at healthy levels, reflecting volume gains, some price increases but generally growth in our market share in this area, this important area for growth for Henry Schein. Most experts are expecting a high incidence of flu this year. The illness in the United States due to winter experience in the southern hemisphere. We would expect a strong flu season to drive patient visits to physician offices, and in turn increased demand for a host of products we provide specifically tests, the traditional point of care test for flu and other diseases including a multi COVID-19 influenza diagnostic test kits. So with that overview on our business, I will turn the call over to Ron, for a more detailed review of our financial results. Ron, please.

Very good. Thank you, Stanley. And good morning everyone. As we begin, I’d like to point out that I will be discussing our results as reported on a GAAP basis and on a non-GAAP basis. Our third quarter non-GAAP financial results for 2022 and 2021 exclude certain items detailed in Exhibit B of today’s press release and in the supplemental information section of our Investor Relations website. I will focus my comments on sales primarily to LCI sales and LCI growth, which has internally generated sales in local currencies and excluding acquisitions compared with the same quarter in the prior year. A detailed breakout of the components of our sales growth, including OCI growth is included in Exhibit A of today’s press release. Our third quarter global LCI sales decreased 2.4% versus the prior year. However, when excluding sales of PPE and COVID-19 test kits, our LCI sales grew 6.8%. Third quarter combined sales of PPE and COVID-19 test kits were $260 million lower than in the third quarter of the prior year. Our GAAP operating margin for the third quarter of 2022 was 6.86%, a 23 basis point improvement compared with prior year GAAP operating margin. Our non-GAAP operating margin for the third quarter was 7.18%, a 55 basis point improvement compared with prior year non-GAAP operating margin. Operating margin improvement was driven by gross margin expansion, mainly as a result of increased growth and sales of higher margin products. Turning to taxes. Our reported GAAP effective tax rate for the third quarter of 2022 was 22.7%. This compares with a 23.9% GAAP effective tax rate for the third quarter of 2021. On a non-GAAP basis, our effective tax rate for the quarter was 22.8%, and this compares with the prior year non-GAAP effective rate of 23.9%. Third quarter 2022 GAAP net income was $150 million or $1.09 per diluted share. This compares with prior year GAAP net income of $162 million or $1.15 per diluted share. Our third quarter 2022 non-GAAP net income was $157 million or $1.15 per diluted share. This compares with prior year non-GAAP net income of $155 million or $1.10 per diluted share. Amortization from acquired intangible assets for the third quarter was $31.6 million or $0.15 per diluted share. This compares with $30.1 million or $0.13 per diluted share for the same period last year. Foreign currency exchange significantly impacted our third quarter diluted EPS by approximately $0.02 versus the third quarter of last year. I’ll provide some detail on our third quarter sales results. Global dental third quarter sales were $1.8 billion with OCI growth of 1.2%. LCI growth excluding sales of PPE was 5.8%. Global dental consumable merchandise LCI sales decreased by 0.8%, but increased by 5.1% when excluding PPE. Global dental equipment LCI growth was 8%. North American dental LCI sales decreased 0.1% compared with the prior year, primarily due to a 3.6% decrease in consumable merchandise LCI sales. However, when excluding sales of PPE, North American dental consumable merchandise LCI growth was 3.8%. North American dental equipment, LCI sales increased 12.8%, primarily driven by traditional equipment sales. The equipment backlog in both our North America and international businesses remains strong. International dental LCI growth was 3.3% driven by consumable merchandise LCI growth of 3.9%. Consumable merchandise LCI growth was 6.9% when excluding sales of PPE, and was driven by strength in Australia, New Zealand, and Brazil. International equipment LCI growth was 1.4%. Let me point out that this was against a tough comparable as international equipment LCI growth in the third quarter of 2021 was 23.9%. Sales of dental specialty products were approximately $223 million in the third quarter, with LCI growth of 2.5% compared with the prior year. Global technology and value-added services sales during the third quarter were $176 million with LCI growth of 4.2% compared with the third quarter of 2021. Sales growth was impacted by the expiration of a government contract. Adjusting for this contract, underlying LCI growth was 8.5%. In North America technology evaluated services LCI growth was 2.5%, and was 7.3% when adjusting for the impact of the government contract was strengthened by our revenue cycle management, patient relationship management, business solutions, and practice management businesses including Dentrix and Dentrix Ascend. Internationally, technology and value-added services LCI growth was 16.5%, driven by strength in the UK. During the third quarter, our technology and value-added services businesses, together with our dental specialty products achieved total sales growth of 0.8% and LCI sales growth of 3.2%. Global medical sales during the third quarter were $1.1 billion and LCI sales decreased 8.8% due to lower sales of PPE products and COVID-19 test kits. In North America, LCI growth was 9.3% when excluding sales of PPE and COVID-19 test kits, led by strong growth in sales of pharmaceuticals, medical equipment, and point of care diagnostic products. We sold approximately $81 million in COVID-19 test kits in the third quarter, including both flu and COVID-19 combination tests. This compares with approximately $207 million of test kits sold in the third quarter of 2021. Regarding stock repurchases, we repurchased common stock in the open market during the third quarter buying approximately 1.2 million shares at an average price of $76.42 per share, for a total of $90.5 million. The impact of the repurchase of shares in our third quarter diluted EPS was material. As of the end of the quarter, we had approximately $400 million authorized and available for future share repurchases. Turning to our balance sheet and cash flow. We continue to benefit from significant liquidity, providing our businesses with the flexibility and financial stability to execute on organic growth initiatives and strategic acquisitions while continuing to return capital to our shareholders. Operating cash flow for the third quarter was $98 million compared with $211 million last year, with the decrease primarily due to an increase in working capital driven by timing of accounts payable. With reference to restructuring as part of our previously disclosed integration and restructuring initiative, we recorded a pre-tax charge in the third quarter of $10 million for $0.05 per diluted share. This plan focuses on the strategic plan in streamlining operations and other initiatives to increase efficiency. The company expects to continue to record integration and restructuring charges for the remainder of 2022 and in 2023. However, an estimate of the amount of these charges has not yet been determined. Any restructuring and integration charges are expected to primarily include severance pay and facility-related costs. The expense savings from this plan are expected to be realized mainly in 2023 and beyond. Turning to 2022 financial guidance, as we are not able to provide estimates at this time for costs associated with integration and restructuring for the remainder of the year. We are not providing GAAP guidance. Also, our guidance for the balance of 2022 is for completed or previously announced acquisitions and does not include potential future acquisitions or integration and restructuring expenses. Guidance also assumes foreign currency exchange rates will remain generally consistent with current levels. However, additional headwinds from foreign currency exchange rates may further impact our sales and EPS. On a non-GAAP basis, we are narrowing our diluted EPS guidance range to $4.79 to $4.87, reflecting growth of 6% to 8% compared to our 2021 non-GAAP diluted EPS of $4.52. This includes a $0.10 adverse impact on foreign exchange rates versus 2021. We also continue to expect full year 2022 non-GAAP operating margin expansion of 20 to 25 basis points over 2021 non-GAAP operating margin. We are revising our full-year sales guidance and now expect sales growth of approximately 1.5% to 2.5% versus our previous guidance for sales growth of 3% to 6%, which mainly reflects a strengthening U.S. dollar and lower PPE sales. We continue to expect 2022 full-year sales of COVID-19 test kits to be 25% to 30% lower than in 2021, and 2022 full-year sales of PPE are expected to decrease 30% to 35% from 2021. 2022 full year sales of PPE and COVID-19 test kits combined are expected to be approximately 30% lower than full-year sales in 2021. This trend of lower sales may continue in the coming year versus 2022. We do expect to continue to achieve gross margins on these products that are generally consistent with our dental and medical businesses. Despite these meaningful market-related headwinds, we continue to be confident in the strength of our underlying businesses and we are taking additional time to finalize our view of the overall effect of PPE pricing and COVID-19 test kits volume for next year. As we have seen in 2022, this has a meaningful impact on our business, and we want to ensure we give it appropriate consideration along with ongoing analysis of macroeconomic trends. We intend to issue 2023 financial guidance with our fourth quarter earnings results. With that, I’ll turn the call back to Stan.

Thank you, Ron. So before we open the call to questions, I would like to take a moment to note the passing of our board director, Diane Rico in August. Diane was an internationally known authority on aesthetic and restorative dentistry, as well as an early pioneer in digital dentistry. She served on our board since 2014 and brought a valuable perspective to Henry Schein, and was a wonderful human being. I would also like to spotlight that early last month Henry Schein was named to Fortune magazine’s annual Change the World list. We were recognized for our leadership initiatives to advance health equity for individuals with disabilities, and in particular our engagement with our key stakeholders in support of this work. Our CSR report, which was released in mid-August, aligned with two of the most common disclosure standards FASB, GRI. This is an important milestone as we prioritize transparency and accountability in our ESG work. So in conclusion, while there are a number of external factors at play, specifically as it relates to PPE, and test kits, and foreign exchange our BOLD plus one strategy remains our North Star. And our team is executing according to plan. As a result, we feel very good about our position in the markets we serve and generally, the team’s focus on priorities and delivery. So with that review of our third quarter financial results and some commentary on our future, I would like to open the call to questions. Operator, please.

Thank you, sir. We will now begin the question-and-answer session. Our first question comes from Jeff Johnson with Baird. Please go ahead with your question.

Thanks. Good morning, guys. Can you hear me okay? Good morning, and congratulations on the quarter. I guess a two-part question. They’re not really connected. But I want to shove both of them together because I do want to ask both questions. But the first one, Ron just on the gross margin up 110 basis points year-over-year. Could you help us bridge how much FX was weighing on that gross margin versus how much maybe price increases in the lower PPE and COVID testing might be offsetting and helping? Those are the three big variables outside of just kind of normal operations that I think we’re all trying to understand what the impact is on the gross margin side. And then if I go back to our September healthcare conference, Stanley, I think you and Ron had made the comment that I think you and Ron had made the comment that you would provide at least some framework for 2023. I’m not really hearing a lot of that. And I know the markets are a little uncertain right now. But if I look at the street, around the street as modeling 6% EPS growth next year, we’re admittedly closer to flat year-over-year in our model just can you help us kind of peg between where the street’s at that 6%, where maybe I’m modeling closer to flat just how to think about maybe the ups or downs from either of those numbers? Thanks.

Well, Jeff, we’ll start with your gross margin question first, I think that especially with given our portfolio, you get a kind of a broad mix of change of products, and that obviously is going to impact that gross margin. So we did see some benefit from some of the higher margin products. We did see, I think, some benefits in the third quarter on merchandise, primarily, in the non-PPE area, obviously, because gloves were down in pricing, but from inflation that we estimate to be in kind of that 3% to 4% range benefiting there as well. So I think that gave us a little bit of a lift on the gross margin versus last year. In terms of 2023, as you mentioned, there’s a lot of different moving parts, as we kind of work to and look to 2023, we just considered it to be prudent at this point in time to provide guidance with our Q4 release so that we can better understand the dynamics of the PPE market, what’s happening with COVID-19 test kits. These are all things that have a significant influence on our income. So when we provide our fourth quarter earnings release, we will provide 2023 guidance at that point in time.

Jeff, let me just highlight. We can’t give guidance now. But in general, we’re feeling pretty good about our core businesses. That is our distribution businesses in the United States globally. Our specialty businesses, although I would say in the implant field, there is a greater demand at this moment for the lower-priced also, premium implants and software businesses and other value-added service businesses. Having said that, the price of PPE, namely, primarily gloves is highly volatile, although we think of stabilizing and test kits, we think have stabilized from the latter the last few quarters. But I think it wouldn’t be appropriate right now to provide guidance for 2023 taking into account the volatility in PPE and I wish we could do more, but I think it would be irresponsible to try to predict those areas.

Next question comes from the line of Elizabeth Anderson with Evercore ISI. Please proceed with your question.

Hi, guys, thanks so much for the question. Stanley I think you sort of alluded to and in Jeff’s question a little bit. But if we think about sort of October and sort of the beginning of the Q2 results, how would you say the trajectory compares to the third quarter? And then just in general, on the overall visibility of the business now right now, obviously, one question many investors have been asking is, has there been ex-COVID and each, like broader changes and how you sort of think about the visibility of the business right now? Thanks.

Yes, I think that’s together with Jeff question is the core which we ponder, and I think we’re quite comfortable. Look, October dental consumable merchandise, internal sales growth, excluding PPE grew relatively consistent with the third quarter, and that’s both in North America and internationally. So those businesses are relatively stable. Of course, we can’t, we just don’t have visibility on the price of gloves. And it could swing in a number of directions. Having said that, I think it’s better to look at the core business. And we’ll break out for you sales of these gloves, the gloves and the test categories. And so you’ll be able to figure out how we’re doing in the core business. And we’re seeing that that is pretty stable. We gave you, and actually doing quite well we gave you sales, excluding those items, and excluding foreign exchange, foreign exchange and Ron will give you the number did have an impact in all three quarters. We’re contemplating in our guidance that we’ve reached a stable foreign exchange, which is, of course, reflective of very strong dollar in the markets that we serve. Now, if I wasn’t clear, I’m happy to give you more clarity or Ron can do that. Now, as it relates to an external by the way, and medical also if you take our PPE and test October was more or less in line with the third quarter as well. And global technology value-added services, sales not that material but in the scheme of Henry Schein, but the profits seem to be stable as well, from the third quarter. So patient traffic, it’s very hard to get this precise. If you take a look at the ADA survey, and we don’t know 100% how this works. Some recent analyst reports suggest that patient traffic has slowed modestly since the end of August. Somewhere we’re reading between 3% to 4%. If we take the ADA and analyst reports into account. According to some analysts, perhaps reading into the ADA report translates into approximately 6% below pre-pandemic levels. Now, our claims data also suggests that volume is down approximately 3% to 4% compared to the previous year. So that is down from where it was going into the year. In addition, the ADA survey identifies a growing number of dentists in the U.S. that are concerned with staffing shortages, particularly of hygienists. So their hygiene is not material, it is the fact that they’re having a problem getting dental assistants. And so there is a concern with satisfying the traffic. But if you look at our U.S. general merchandise, and everything I’ve said now relates to the U.S., if you take a look at our U.S. merchandise sales, they’re growing if you take our PPE by about 4% and holding steady. So our inflation expectations are that we had not expectations, our view is that we have 3% to 5% product inflation and so that means our volumes are relatively flat. We are seeing a slowdown, as I mentioned in the implant business, but also for strong 2021. So the business is basically stable. We believe we’re gaining some market share, can prove it to you. The earnings power of the business, I think has positive upside in that we are working on managing expenses and moving towards higher margin earnings. So that’s sort of basically the U.S. side. Outside of the U.S. it seems pretty stable as well. Countries are different. But it seems relatively stable. So that’s a long answer. But you cut through it all it’s relatively stable with us being optimistic on the positive side, removing PPE on the dental side, and removing PPE and tests on the medical side. And that relates to both domestic and international. I can’t give you a crisp answer. Those are the puts and the takes.

Our next question comes from the line of Brandon Vazquez with William Blair. Please proceed with your question.

Hi everyone, thanks for taking the question. In terms of profitability, there’s a lot of macro headwinds that are uncertain here. And I can appreciate it’s hard to put a finer point on those. But how do you guys think about balancing investments in future growth, and kind of balancing those near-term headwinds to deliver some profitability and EPS? So what are some key investments you’ll continue to put capital into, regardless of what happens and kind of the trajectory things you can’t change and where areas that you can pull back on spend?

Well, when you say investments, let me deal with the M&A side. As I noted earlier on, deals are not done until they are signed and announced. But we have a view that we wish to spend $300, $400 million a year on M&A. We’ve done approximately that on average. Some years it’s been a lot higher. Last year was a bit higher. During COVID, it was a bit lower. But we want to do, we want to continue to invest in M&A at that kind of rate. The pipeline is relatively full. Specialty products is an area of focus. We’ve already announced two fold-ins on the distribution side. But I would say it’s the high margin high growth areas that we’re most interested in. It doesn’t mean we will not continue to fold in businesses, expand our geography on the distribution side. Again, we remain quite optimistic in that the pipeline is full. But we can’t commit to closing anything. As it relates to investments in the business, I would ask Ron to cover that. We have specific areas where we’re focusing on reducing expenses but other areas where we’re going to move investments towards that we believe will impact the long-term sustainable profits of the business. Ron on the investment in the business, your thoughts?

Yes. Brandon part of this restructuring initiative we have in place is to give us an opportunity to redirect some investment internally in the business to those areas where we see greater opportunities for growth, greater opportunities for higher profitability. So that’s part of it. But we’re also, like I mentioned in the prepared remarks, we have $400 million authorized for share repurchases, and we will expect that to continue to be an important part of our capital allocation going forward as well. So part of this is share buyback together with I think kind of targeted M&A as Stanley pointed out, but plus also some reallocation of internal investment and as we proceed through 2023.

And our next question comes from the line of A.J. Rice with Credit Suisse. Please proceed with your question.

Hi, everybody. Thanks for the question. I wondered if maybe to expand a little bit on your comments on inflation. And I know in the prepared remarks, you talked about seeing some price increases at the end of the quarter. Are you still able, generally to pass those along? Are you seeing any significant shift toward your the national brand or your corporate brand, as an offset to those inflationary pressures? And maybe also, as you progress through the year is the trend of that inflationary increases been pretty steady throughout the year? I know year-over-year it’s up but pretty steady throughout the year, or you’ve seen it build over the course of the year?

So good question. There have been good actually. Let me begin with the end. We did see some national brands some a bunch of increases at the end of the second quarter by some manufacturers. And I would say that there’s a growing awareness amongst our customer base of manufacturers that have increased significantly, multiple times, and those that have held their prices back. So there’s a much more acute understanding of price increases in the marketplace now than I would say, six months ago, two or three quarters ago. There’s nothing very little that is so unique in dentistry, that a customer can move from one manufacturer to another. Obviously, certain brands provide more comfort, as brands generally do. Statements generally make about branding than other brands. So generally, we’ve been able to pass on price increases and manufacturers have not been supportive of that. In other words, they may not want to recognize the chargeback. It’s very rare. I can’t think of too many manufacturers, but that’s not a good. It’s generally the norm in medicine. It’s been the case in medicine for two decades. There are a couple of well, one, maybe one or so manufacturers that are in dentistry that are having an issue with that. But generally we’re able to pass them along and where we’re not meant I would say the customers are working with us and where there isn’t a national brand option we do offer our private brand and some customers look to private brands in any event. So it’s not a crisp answer in that is not one shoe that fits all. But generally we’re able to move price increases along. The suppliers are understanding where manufacturers are going further than others, that there are options, whether it’s with other national brands, big ones, smaller ones, or our private brand. So I believe we have very good relations with our customers, with most of our suppliers, and we’re managing to this in a rather effective way. Our margins, gross profit has done okay. It’s not only because of this particular issue that we describe, but it’s also a movement towards a higher growth, higher margin businesses.

Okay, maybe just a follow-up on the comment you made that lead times on the equipment side are starting to improve a little bit. Does that change the dynamic in the marketplace where there are potential customers that just said, look, it’s a long lead time. So I’m not going to order now that may now start to order or does it affect the sales process in any other way?

Yes, I believe we noted that our order book has strengthened compared to the end of last quarter. This improvement comes from various factors, notably increased activity in the CAD CAM sector and the digital side, which was influenced by the scheduling of meetings in different quarters. Overall, we experienced a solid quarter, particularly in the U.S., although international figures were slightly impacted by previous performance. The increase in our order book is partly due to fluctuating supply dynamics. In terms of traditional equipment, we’ve been able to supply customers who urgently needed products, while encouraging others to wait if they didn’t have immediate needs. The main challenge has been related to traditional equipment in the U.S., particularly with two major manufacturers. One has resolved its backlog issues and prioritizes our orders, while the other still faces some backlogs despite increased capacity. The larger concern revolves around product availability and delays in installation caused by general labor shortages and contractor delays, which have hindered our ability to deliver. However, I believe these issues are relatively minor, as demand for our equipment remains strong. We may also be gaining market share, but overall, our equipment business in the U.S. and globally is performing very well.

And our next question comes from the line of Jon Block with Stifel. Please proceed with your question.

Great, thanks, guys. And good morning. Appreciate the time. And maybe just two quick questions. First, on the dental consumable side. It seems like your LCI growth premium between specialty and basic consumables ex-PPE has compressed and Stanley I think you talked about some implant headwinds. Should we expect that ratio compression, I guess to continue in coming quarters and if so, why Stanley? Is that just sort of teasing out some shifts going on in the dental industry of maybe that move back to call it bread and butter dentistry or more hygiene dominating the chair versus higher-end procedures? And then I’ve got a quicker follow-up on equipment. Thanks.

Yes. Hard to tell. We haven’t seen the data yet on worldwide sales of implants for some data available. We haven’t seen the report yet. But my sense is the units in oral surgery have not gone down significantly, maybe slightly. But there is a greater interest in the lower priced implants; it’s still a little bit strange that the actual cost of the implants is insignificant compared to the procedure. But I guess dentists in certain markets are looking at that. We’re still optimistic about the oral surgery business, very optimistic. Both the market is stable and because we continue to do well in parts of Europe and in the United and North America on implants. I think the low priced units gain our business in that area is doing very well. So we’re also dealing with high comps. The quarters, previous ‘21 was very high comps, very high numbers. So I wouldn’t draw any specific conclusions as to the strength of those businesses from our point of view. I think they are pretty solid. On the other side, our endo business has done very well. And our traditional wires and brackets business, although it’s very small, has not done well. But our aligners have done well. Let me hasten to say, with a very small market share, but we have a couple of DSO contracts that were they work exposed exclusively with us.

And maybe just a follow-up. And I’ll try to push you a little bit. Your dental equipment comments and continue to, I think be pretty upbeat overall on dental equipment. And that’s contrary at least just to Arch Axis and it’s telling your conviction that this is true, call it end-user demand is not a function of a catch-up from the supply issues of six to 12 months ago. And do you think that equipment strength continues into 2023? Thanks for your time, guys.

Yes. We’re talking about at the margin, a relatively small percentage, one way or the other. But generally, I think the business is solid. We also do well with DSOs globally on the equipment side, I think that helps. We have capabilities, I think, on installation, able to bring up many new DSOs, practices on one day, if they buy practices, a whole group of practices, we’re able to help install new equipment relatively quickly. We work very well with our suppliers. Not all but most of our suppliers on the equipment side is a great way to markets. So there are a lot of factors in there. But I would say at least for the foreseeable future, our dental conviction is pretty good. I can’t comment on the rest of the market. There are many players with some private players, even the public players don’t disclose exactly what’s going on. Again, chairs, units, and lights are largely, are largely private companies. And so it’s very hard to give you a comparison to the market. Having said that we do feel comfortable with our equipment growth as of November 1, 2022.

And our next question comes from the line of Erin Wright with Morgan Stanley. Please proceed with your question.

Great, thanks. I have a quick question on the medical segment. What’s driving the highest single-digit growth? I guess was a little bit slower than what we saw in the first half. But that’s excluding the COVID-related dynamics and what the sustainability of this growth, are you seeing market share gains? Or what are some of the factors driving that? Thanks.

Yes. That’s also another good question. We don’t get many questions on the medical business which we think is a great franchise. We’re doing very well with IDNs. Now IDNs generally use other map distributors, big, big hospital distributors for their hospital acute care needs. But for the ultimate care needs, the physician practices primary but other ultimate care sectors other than long-term care which we are not in generally, we are viewed as an important player. We don’t win every contract, but we win a lot. It’s based on our service, our relationship with suppliers, efficient charge-back systems that we have in place with suppliers that work very well with us on that side of the house, where there’s been charge-backs for example, in place for years as a way of doing business, and we just do it very well on the ultimate care side, particularly for physician side. So with the large IDNs too many new ones, we have won a few in the last few years, but that have switched that often. Having said that, there’s a growing part of the IDN business that’s moving from the acute care setting into the ultimate care specifically, physician ASC side of the provider side. And we do well with that. We also made a comment that our other medical businesses are doing well. Government business we do quite well in that area. We have some unique businesses in that area. And they’re not huge, but they’re doing well. We’ve also indicated that our sports medicine, there are parts of the EMS business that we’re in that dwell podiatry the smaller practices, the smaller group practices, these are all areas where we have folks directly focused on these businesses that are doing well. So I think we do well in this marketplace. We have scale. And we have a sophisticated supply chain. I’m not sure if anyone does it better than us from a logistics point of view, combining med surg, pharmaceuticals, equipment, installation, the whole package all in one from one distributor with formularies charge-backs that really work very well.

And then on 2023, just, I get it there’s limited visibility on PPE and test kits and also the macro kind of heading into 2023. But are there other factors that could be limiting your visibility there for instance are there upcoming changes in DSO or manufacturing contracts that would impact your ability to provide guidance into 2023 now like, or do you anticipate that it’s a fairly normal environment next year from a customer and manufacturer relationship standpoint? Thanks.

No. Hi Erin, it’s Ron. I would say that it’s more the latter from what you just said. We’re not anticipating any other significant changes in the market. We’re just trying to better digest what’s happening on PPE and the COVID-19 test kits. I mean, we’re happy with how the business is doing. We’re happy with the quarter. We faced a $260 million revenue headwind this quarter in terms of decreased revenues in PPE and COVID test kits and in grew EPS from, non-GAAP EPS from $1.10 to $1.15. So, we’re happy with the core business, but we need to get it, we want to better understand the whole dynamics of what’s happening with PPE and COVID test kits we’ll be able to provide, I think detail that will be helpful to people when we include 2023 financial guidance with our Q4 earnings release.

Thank you. We have time for one last question coming from the line of Jason Bednar from Piper Sandler. Please proceed with your question.

Hey, good morning. Thanks for squeezing me in here. And congrats on the results today. Yes I’ll go with a two partner here. And I’ll just ask both of them upfront, they’re both follow-ups to prior questions. So maybe with the forward-looking question here, and I’ll take a different cracker than what Jeff did on 2023. Are you willing to commit at all to earnings growth for next year? Or is there any I guess any reason to think operating margins don’t expand in 2023 given the restructuring that you have underway? And then building on Jon Block’s question, if we’re thinking about the sales contribution, shifting maybe on the margin away from the more profitable specialty areas, those parts of the business softening up a little bit, it sounds like. Can you reconcile or fill the gap and how profitability and margin expansion is still remaining that solid as you see it for 2022 in spite of this dynamic, thank you.

Yes Jason regarding 2023, like I said, we’ll be providing plenty of details around our 2023 financial guidance with our Q4 earnings release. So I think at this point in time, we’re not prepared to provide anything directional. With reference to your question on the kind of dental margins and the influence of specialty products, I think something to keep in mind is that specialty products are likely going to have or historically may have a little more volatility in their growth versus merchandise. Merchandise can fluctuate a few points year-over-year while specialty products might have a little greater volatility than that. As Stanley said, we had pretty good growth last year in the third quarter of the specialty product. So you’re right in terms of that particular quarter maybe there’s a little more kind of, I’m not sure what the right word is, but how the margins kind of come together. But I don’t know if we’re to the point of saying that’s going to be kind of a long-term trend here.

We still highly bullish about high growth, high margin businesses. There may be some volatility as Ron indicated, but generally, the oral surgery business is a good one. We believe growing our market share globally. And endo is very strong. Obviously, some volatility in brackets, and aligners seem, with a small for us seem to be also positive area. But I wouldn’t read anything into one or two or three quarters. I think we’ve shown that long term our businesses are growing and we expect commitments to add in organic growth to that.

Thank you, I would like to turn the floor back over to Stanley Bergman for any closing comments.

Thank you, operator. Thank you, everyone, for your participation. I think we’ve said it a couple of times today, many times, we have confidence in our core businesses. We just don’t know the degree of volatility in the PPE, primarily gloves, and the COVID test area, the rapid test area. But excluding that, we feel strength, stability. We are feeling good about our dental consumable businesses around the world, the equipment business. We are feeling good about our medical business and our value-added services businesses recovered specialty. So obviously, we’re in volatile times. But we’re also focusing on our expenses as we’ve announced in the past relative to our restructuring and this is something Henry Schein has gone through many times in the past, have a good management team in place, focused on the priorities at the center, which is a BOLD plus one initiative. So with that in mind, thank you all again for calling in. We’ll speak to you at the beginning of mid-February, the longer period, mid-February, but I think we’ll be at a couple of conferences, will be two or three conferences. Right? And again, if anyone has any specific questions, please feel free to reach out to Ron, to Graham and Ron and thank you very much. Since we won’t have another one of these calls, have a safe holiday season and thank you very much for your interest in Henry Schein.